WASHINGTON – The winds of change blew against Biogen Idec Inc. Wednesday, with shares sailing downward 5.8 percent, after the FDA approved the first oral disease-modifying agent for multiple sclerosis, Gilenya (fingolimod), from competitor Novartis AG. (BioWorld Today) Read More
